Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 562 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make HALO a good candidate for value and growth and quality investing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 22.1% | ||
ROE | 100.64% | ||
ROIC | 23.44% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 55.1% | ||
PM (TTM) | 44.76% | ||
GM | 83.45% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.13 | ||
Debt/FCF | 3.04 | ||
Altman-Z | 5.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.39 | ||
Quick Ratio | 7.3 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.48 | ||
Fwd PE | 9.67 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 16.41 | ||
EV/EBITDA | 12.26 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |